FAT1 and neoplasm: Inhibitors targeting YAP or TEAD. Although a few studies have demonstrated drugs that effectively target YAP, antisense oligonucleotides ION-537 reduce YAP protein levels, thereby suppressing tumor growth in a mouse model of hepatocellular cancer and a xenograft model of HNSCC cell lines harboring FAT1 mutation, which is in Phase I clinical trial [120] (Table 1).